| Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy. | |
| | |
| Jump to Full Text | |
MedLine Citation:
|
PMID: 21029522 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
For monitoring efficacy of sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy, data obtained from studies of children seemed inadequate. High prevalence of triple and quadruple mutants in the dihydropteroate synthase and dihydrofolate reductase genes of Plasmodium falciparum parasites contrasts with the efficacy of sulfadoxine/pyrimethamine in reducing low birthweights and placental infection rates. In light of this discrepancy, emphasis on using molecular markers for monitoring efficacy of intermittent preventive treatment during pregnancy appears questionable. The World Health Organization recently proposed conducting in vivo studies in pregnant women to evaluate molecular markers for detecting resistance precociously. Other possible alternative strategies are considered. |
| | |
Authors:
|
Philippe Deloron; Gwladys Bertin; Valérie Briand; Achille Massougbodji; Michel Cot |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Emerging infectious diseases Volume: 16 ISSN: 1080-6059 ISO Abbreviation: Emerging Infect. Dis. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-29 Completed Date: 2011-03-02 Revised Date: 2012-03-06 |
Medline Journal Info:
|
Nlm Unique ID: 9508155 Medline TA: Emerg Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 1666-70 Citation Subset: IM |
Affiliation:
|
Institut de Recherche pour le Developpement, Paris, France. philippe.deloron@ird.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antimalarials
/
administration & dosage,
therapeutic use* Drug Combinations Female Humans Malaria / pathology, prevention & control* Placenta / parasitology, pathology Pregnancy Pregnancy Complications, Parasitic / pathology, prevention & control* Pyrimethamine / administration & dosage, therapeutic use* Sulfadoxine / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antimalarials; 0/Drug Combinations; 2447-57-6/Sulfadoxine; 37338-39-9/sulfadoxine-pyrimethamine; 58-14-0/Pyrimethamine |
| Full Text | |
|
Journal Information Journal ID (nlm-ta): Emerg Infect Dis Journal ID (publisher-id): EID ISSN: 1080-6040 ISSN: 1080-6059 Publisher: Centers for Disease Control and Prevention |
Article Information Print publication date: Month: 11 Year: 2010 Volume: 16 Issue: 11 First Page: 1666 Last Page: 1670 ID: 3294539 PubMed Id: 21029522 Publisher Id: 10-1064 DOI: 10.3201/eid1611.101064 |
| Sulfadoxine/Pyrimethamine Intermittent Preventive Treatment for Malaria during Pregnancy Alternate Title:Treatment for Malaria during Pregnancy | |
| Philippe Deloron | |
| Gwladys Bertin | |
| Valérie Briand | |
| Achille Massougbodji | |
| Michel Cot | |
| Author affiliations: Institut de Recherche pour le Développement, Paris, France (P. Deloron, G. Bertin, V. Briand, M. Cot); |
|
| Université Paris Descartes, Paris (P. Deloron, G. Bertin, V. Briand, M. Cot); |
|
| Faculté des Sciences de la Santé, Cotonou, Benin (A. Massougbodji) |
|
| Correspondence: Address for correspondence: Philippe Deloron, Mère et Enfant Face aux Infections Tropicales, Unité Mixte de Recherche 216, Faculté de Pharmacie, Institut de Recherche pour le Développement, 4 Ave de l’Observatoire, 75270 Paris CEDEX 06, France; email: philippe.deloron@ird.fr |
|
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at www.medscapecme.com/journal/eid; (4) view/print certificate.
Upon completion of this activity, participants will be able to:
- Identify pregnant women who are most susceptible to pregnancy-associated malaria and the current recommendations for intermittent preventive treatment in pregnancy for malaria prophylaxis
- Examine adverse events resulting from malaria during pregnancy and the efficacy of varying chemoprophylactic regimens in prevention.
Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.
Desiree Lie, MD, MSEd, Clinical Professor; Director of Research and Faculty Development, Department of Family Medicine, University of California, Irvine at Orange. Disclosure: Désirée Lie, MD, MSEd, has disclosed the following relevant financial relationship: served as a nonproduct speaker for “Topics in Health” for Merck Speaker Services.
Disclosures:Philippe Deloron, MD, PhD; Gwladys Bertin, MSc; Valérie Briand, MD, PhD, MPH; Achille Massougbodji, MD;andMichel Cot, MD, PhD,have disclosed no relevant financial relationships.
Notes
Suggested citation for this article: Deloron P, Bertin G, Briand V, Massougbodji A, Cot M. Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy. Emerg Infect Dis [serial on the Internet]. 2010 Nov [date cited]. http://dx.doi.org/10.3201/eid1611.101064
Article Categories:
Keywords: Keywords: Malaria, pregnancy, prevention, sulfadoxine/pyrimethamine, intermittent preventive treatment in pregnancy, parasites, CME, synopsis. |
|
Previous Document: Regulatory oversight and safety of probiotic use.
Next Document: Oropharyngeal cancer epidemic and human papillomavirus.